STOCK TITAN

[NPORT-P] Innovator Equity Managed Floor ETF SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
NPORT-P
Rhea-AI Filing Summary

Regulus Therapeutics Inc. filed Post-Effective Amendment No. 1 to 20 previously effective Form S-8 registration statements on 25 June 2025. The amendment deregisters all shares of common stock that had been registered but remain unsold or unissued under the company’s 2009, 2012, 2019 and 2021 equity incentive plans, multiple inducement plans and its 2012 and 2022 employee stock purchase plans. Collectively, the affected filings span registrations made between 2012 and 2025 and reference two reverse stock splits (1-for-12 in 2018 and 1-for-10 in 2022).

The action follows completion of the merger stipulated in the 29 April 2025 Agreement and Plan of Merger among Regulus, Novartis AG and Redwood Merger Sub Inc. On 25 June 2025, Redwood Merger Sub merged with and into Regulus, leaving Regulus as a wholly-owned subsidiary of Novartis. Because the company is now private, it has terminated all offerings of its securities, rendering the original S-8 registrations unnecessary.

Operationally, Regulus is identified as a non-accelerated filer and a smaller reporting company. No financial statements, valuation data or pro-forma disclosures are included; the filing is purely administrative. For investors, the document confirms the cessation of future share issuances under employee and incentive plans and provides final regulatory closure on Regulus’ transition from a public issuer to part of Novartis.

Regulus Therapeutics Inc. ha depositato l'Emendamento Post-Esecutivo n. 1 a 20 dichiarazioni di registrazione Form S-8 precedentemente efficaci il 25 giugno 2025. L'emendamento cancella la registrazione di tutte le azioni ordinarie che erano state registrate ma non ancora vendute o emesse nell'ambito dei piani di incentivazione azionaria 2009, 2012, 2019 e 2021, di diversi piani di incentivo e dei piani di acquisto azionario dipendenti del 2012 e 2022. Complessivamente, le registrazioni interessate coprono un periodo dal 2012 al 2025 e fanno riferimento a due frazionamenti azionari inversi (1-per-12 nel 2018 e 1-per-10 nel 2022).

L'azione segue il completamento della fusione prevista dall'Accordo e Piano di Fusione del 29 aprile 2025 tra Regulus, Novartis AG e Redwood Merger Sub Inc. Il 25 giugno 2025, Redwood Merger Sub si è fusa con Regulus, che è diventata una controllata interamente posseduta da Novartis. Poiché la società è ora privata, ha terminato tutte le offerte dei suoi titoli, rendendo inutili le registrazioni S-8 originali.

Dal punto di vista operativo, Regulus è classificata come non-accelerated filer e come società di dimensioni minori. Non sono inclusi bilanci, dati di valutazione o informazioni pro-forma; la registrazione ha carattere puramente amministrativo. Per gli investitori, il documento conferma la cessazione delle future emissioni di azioni nell’ambito dei piani dipendenti e di incentivazione e fornisce la chiusura regolamentare definitiva sulla transizione di Regulus da emittente pubblico a parte di Novartis.

Regulus Therapeutics Inc. presentó la Enmienda Post-Efectiva No. 1 a 20 declaraciones de registro Form S-8 previamente vigentes el 25 de junio de 2025. La enmienda elimina el registro de todas las acciones ordinarias que habían sido registradas pero permanecían sin vender o emitir bajo los planes de incentivos de capital de 2009, 2012, 2019 y 2021, varios planes de inducción y los planes de compra de acciones para empleados de 2012 y 2022. En conjunto, las presentaciones afectadas abarcan registros realizados entre 2012 y 2025 y hacen referencia a dos divisiones inversas de acciones (1 por 12 en 2018 y 1 por 10 en 2022).

La acción sigue a la finalización de la fusión estipulada en el Acuerdo y Plan de Fusión del 29 de abril de 2025 entre Regulus, Novartis AG y Redwood Merger Sub Inc. El 25 de junio de 2025, Redwood Merger Sub se fusionó con Regulus, dejando a Regulus como una subsidiaria de propiedad total de Novartis. Debido a que la compañía ahora es privada, ha terminado todas las ofertas de sus valores, haciendo innecesarios los registros S-8 originales.

Operativamente, Regulus se identifica como un presentador no acelerado y una compañía de menor tamaño. No se incluyen estados financieros, datos de valoración ni divulgaciones pro forma; la presentación es puramente administrativa. Para los inversores, el documento confirma la cesación de futuras emisiones de acciones bajo planes de empleados e incentivos y proporciona un cierre regulatorio final sobre la transición de Regulus de emisor público a parte de Novartis.

Regulus Therapeutics Inc.는 2025년 6월 25일에 이전에 효력이 있었던 20건의 Form S-8 등록 명세서에 대한 사후 효력 수정안 1호를 제출했습니다. 이 수정안은 2009년, 2012년, 2019년, 2021년 주식 인센티브 계획, 여러 유인 계획, 그리고 2012년과 2022년 직원 주식 구매 계획 하에 등록되었으나 아직 판매되지 않았거나 발행되지 않은 모든 보통주를 등록 해제합니다. 해당 제출 서류들은 2012년부터 2025년까지의 등록을 포함하며, 2018년 1대 12 및 2022년 1대 10의 두 차례 역병합을 참조합니다.

이 조치는 2025년 4월 29일 Regulus, Novartis AG, Redwood Merger Sub Inc. 간의 합병 계약 및 계획 완료에 따른 것입니다. 2025년 6월 25일 Redwood Merger Sub가 Regulus와 합병되어 Regulus는 Novartis의 전액 출자 자회사가 되었습니다. 회사가 이제 비상장사가 되었기 때문에 모든 증권 공모를 종료하여 원래의 S-8 등록이 불필요해졌습니다.

운영상으로 Regulus는 비가속 신고자이자 소규모 보고 회사로 분류됩니다. 재무제표, 평가 데이터 또는 프로포르마 공시는 포함되어 있지 않으며, 이 제출은 순수하게 행정적 성격입니다. 투자자에게 이 문서는 직원 및 인센티브 계획에 따른 미래 주식 발행 중단을 확인하고 Regulus가 공개 발행사에서 Novartis의 일부로 전환된 것에 대한 최종 규제 종료를 제공합니다.

Regulus Therapeutics Inc. a déposé l'Amendement Post-Effectif n° 1 à 20 déclarations d'enregistrement Form S-8 précédemment en vigueur le 25 juin 2025. L'amendement désenregistre toutes les actions ordinaires qui avaient été enregistrées mais restent invendues ou non émises dans le cadre des plans d'incitation en actions de 2009, 2012, 2019 et 2021, de plusieurs plans d'incitation et des plans d'achat d'actions employés de 2012 et 2022. Collectivement, les dépôts concernés couvrent des enregistrements réalisés entre 2012 et 2025 et font référence à deux regroupements d'actions inverses (1 pour 12 en 2018 et 1 pour 10 en 2022).

Cette action fait suite à la finalisation de la fusion stipulée dans l'Accord et Plan de Fusion du 29 avril 2025 entre Regulus, Novartis AG et Redwood Merger Sub Inc. Le 25 juin 2025, Redwood Merger Sub a fusionné avec Regulus, faisant de Regulus une filiale en propriété exclusive de Novartis. Étant donné que la société est désormais privée, elle a mis fin à toutes les offres de ses titres, rendant les enregistrements S-8 originaux inutiles.

Opérationnellement, Regulus est identifié comme un déposant non accéléré et une société de plus petite taille. Aucun état financier, donnée d’évaluation ou divulgation pro forma n’est inclus ; le dépôt est purement administratif. Pour les investisseurs, le document confirme l'arrêt des futures émissions d’actions dans le cadre des plans employés et incitatifs et apporte une clôture réglementaire finale sur la transition de Regulus d’émetteur public à une entité de Novartis.

Regulus Therapeutics Inc. reichte am 25. Juni 2025 die Post-Effective Amendment Nr. 1 zu 20 zuvor wirksamen Form S-8-Registrierungserklärungen ein. Die Änderung deregistriert alle Stammaktien, die registriert, aber unter den Aktienanreizplänen von 2009, 2012, 2019 und 2021, mehreren Anreizplänen sowie den Mitarbeiteraktienkaufplänen von 2012 und 2022 unverkauft oder nicht ausgegeben geblieben waren. Die betroffenen Einreichungen umfassen Registrierungen aus den Jahren 2012 bis 2025 und beziehen sich auf zwei Rückwärtssplits (1:12 im Jahr 2018 und 1:10 im Jahr 2022).

Diese Maßnahme folgt dem Abschluss der im Fusionsvertrag vom 29. April 2025 zwischen Regulus, Novartis AG und Redwood Merger Sub Inc. festgelegten Fusion. Am 25. Juni 2025 fusionierte Redwood Merger Sub mit Regulus, wodurch Regulus eine hundertprozentige Tochtergesellschaft von Novartis wurde. Da das Unternehmen nun privat ist, wurden alle Wertpapierangebote eingestellt, wodurch die ursprünglichen S-8-Registrierungen überflüssig wurden.

Operativ wird Regulus als Non-Accelerated Filer und als kleineres berichtspflichtiges Unternehmen eingestuft. Es sind keine Finanzberichte, Bewertungsdaten oder Pro-forma-Offenlegungen enthalten; die Einreichung dient rein administrativen Zwecken. Für Investoren bestätigt das Dokument das Ende zukünftiger Aktienausgaben im Rahmen von Mitarbeiter- und Anreizplänen und bietet einen abschließenden regulatorischen Abschluss der Umstellung von Regulus vom öffentlichen Emittenten zu einem Teil von Novartis.

Positive
  • Merger completed: Filing confirms the 25 June 2025 merger with Novartis AG is closed, providing final transactional certainty.
  • No further dilution: Deregistration of all unsold S-8 shares eliminates any future equity issuance under employee or inducement plans.
Negative
  • End of public issuance: Investors lose access to future participation in Regulus equity plans as the company is now private under Novartis.

Insights

TL;DR: Filing cancels employee-plan shares as Regulus becomes Novartis subsidiary.

This Post-Effective Amendment is a housekeeping step required once a public issuer is absorbed by a parent company. By formally withdrawing unsold securities from 20 historic S-8 statements, Regulus eliminates ongoing reporting obligations tied to those plans and prevents any inadvertent issuance of new equity now that it is wholly owned by Novartis AG. Because consideration for the merger is already fixed and no new shares can be issued, the amendment has neutral economic impact on legacy shareholders but finalises the company’s exit from SEC-registered status.

TL;DR: Deregistration ends dilution risk; merger liquidity already realized.

For portfolio holders who tendered shares in the Novartis acquisition, this filing merely tidies the cap-table: every remaining share previously reserved for option or ESPP programs is now voided. While the step is administratively positive—no future dilution can arise—it carries no incremental cash flow or valuation impact beyond what the merger delivered on 25 June 2025. The document thus serves as a practical confirmation that RGLS securities will no longer trade or be issued and that investors should look to Novartis disclosures for any future exposure.

Regulus Therapeutics Inc. ha depositato l'Emendamento Post-Esecutivo n. 1 a 20 dichiarazioni di registrazione Form S-8 precedentemente efficaci il 25 giugno 2025. L'emendamento cancella la registrazione di tutte le azioni ordinarie che erano state registrate ma non ancora vendute o emesse nell'ambito dei piani di incentivazione azionaria 2009, 2012, 2019 e 2021, di diversi piani di incentivo e dei piani di acquisto azionario dipendenti del 2012 e 2022. Complessivamente, le registrazioni interessate coprono un periodo dal 2012 al 2025 e fanno riferimento a due frazionamenti azionari inversi (1-per-12 nel 2018 e 1-per-10 nel 2022).

L'azione segue il completamento della fusione prevista dall'Accordo e Piano di Fusione del 29 aprile 2025 tra Regulus, Novartis AG e Redwood Merger Sub Inc. Il 25 giugno 2025, Redwood Merger Sub si è fusa con Regulus, che è diventata una controllata interamente posseduta da Novartis. Poiché la società è ora privata, ha terminato tutte le offerte dei suoi titoli, rendendo inutili le registrazioni S-8 originali.

Dal punto di vista operativo, Regulus è classificata come non-accelerated filer e come società di dimensioni minori. Non sono inclusi bilanci, dati di valutazione o informazioni pro-forma; la registrazione ha carattere puramente amministrativo. Per gli investitori, il documento conferma la cessazione delle future emissioni di azioni nell’ambito dei piani dipendenti e di incentivazione e fornisce la chiusura regolamentare definitiva sulla transizione di Regulus da emittente pubblico a parte di Novartis.

Regulus Therapeutics Inc. presentó la Enmienda Post-Efectiva No. 1 a 20 declaraciones de registro Form S-8 previamente vigentes el 25 de junio de 2025. La enmienda elimina el registro de todas las acciones ordinarias que habían sido registradas pero permanecían sin vender o emitir bajo los planes de incentivos de capital de 2009, 2012, 2019 y 2021, varios planes de inducción y los planes de compra de acciones para empleados de 2012 y 2022. En conjunto, las presentaciones afectadas abarcan registros realizados entre 2012 y 2025 y hacen referencia a dos divisiones inversas de acciones (1 por 12 en 2018 y 1 por 10 en 2022).

La acción sigue a la finalización de la fusión estipulada en el Acuerdo y Plan de Fusión del 29 de abril de 2025 entre Regulus, Novartis AG y Redwood Merger Sub Inc. El 25 de junio de 2025, Redwood Merger Sub se fusionó con Regulus, dejando a Regulus como una subsidiaria de propiedad total de Novartis. Debido a que la compañía ahora es privada, ha terminado todas las ofertas de sus valores, haciendo innecesarios los registros S-8 originales.

Operativamente, Regulus se identifica como un presentador no acelerado y una compañía de menor tamaño. No se incluyen estados financieros, datos de valoración ni divulgaciones pro forma; la presentación es puramente administrativa. Para los inversores, el documento confirma la cesación de futuras emisiones de acciones bajo planes de empleados e incentivos y proporciona un cierre regulatorio final sobre la transición de Regulus de emisor público a parte de Novartis.

Regulus Therapeutics Inc.는 2025년 6월 25일에 이전에 효력이 있었던 20건의 Form S-8 등록 명세서에 대한 사후 효력 수정안 1호를 제출했습니다. 이 수정안은 2009년, 2012년, 2019년, 2021년 주식 인센티브 계획, 여러 유인 계획, 그리고 2012년과 2022년 직원 주식 구매 계획 하에 등록되었으나 아직 판매되지 않았거나 발행되지 않은 모든 보통주를 등록 해제합니다. 해당 제출 서류들은 2012년부터 2025년까지의 등록을 포함하며, 2018년 1대 12 및 2022년 1대 10의 두 차례 역병합을 참조합니다.

이 조치는 2025년 4월 29일 Regulus, Novartis AG, Redwood Merger Sub Inc. 간의 합병 계약 및 계획 완료에 따른 것입니다. 2025년 6월 25일 Redwood Merger Sub가 Regulus와 합병되어 Regulus는 Novartis의 전액 출자 자회사가 되었습니다. 회사가 이제 비상장사가 되었기 때문에 모든 증권 공모를 종료하여 원래의 S-8 등록이 불필요해졌습니다.

운영상으로 Regulus는 비가속 신고자이자 소규모 보고 회사로 분류됩니다. 재무제표, 평가 데이터 또는 프로포르마 공시는 포함되어 있지 않으며, 이 제출은 순수하게 행정적 성격입니다. 투자자에게 이 문서는 직원 및 인센티브 계획에 따른 미래 주식 발행 중단을 확인하고 Regulus가 공개 발행사에서 Novartis의 일부로 전환된 것에 대한 최종 규제 종료를 제공합니다.

Regulus Therapeutics Inc. a déposé l'Amendement Post-Effectif n° 1 à 20 déclarations d'enregistrement Form S-8 précédemment en vigueur le 25 juin 2025. L'amendement désenregistre toutes les actions ordinaires qui avaient été enregistrées mais restent invendues ou non émises dans le cadre des plans d'incitation en actions de 2009, 2012, 2019 et 2021, de plusieurs plans d'incitation et des plans d'achat d'actions employés de 2012 et 2022. Collectivement, les dépôts concernés couvrent des enregistrements réalisés entre 2012 et 2025 et font référence à deux regroupements d'actions inverses (1 pour 12 en 2018 et 1 pour 10 en 2022).

Cette action fait suite à la finalisation de la fusion stipulée dans l'Accord et Plan de Fusion du 29 avril 2025 entre Regulus, Novartis AG et Redwood Merger Sub Inc. Le 25 juin 2025, Redwood Merger Sub a fusionné avec Regulus, faisant de Regulus une filiale en propriété exclusive de Novartis. Étant donné que la société est désormais privée, elle a mis fin à toutes les offres de ses titres, rendant les enregistrements S-8 originaux inutiles.

Opérationnellement, Regulus est identifié comme un déposant non accéléré et une société de plus petite taille. Aucun état financier, donnée d’évaluation ou divulgation pro forma n’est inclus ; le dépôt est purement administratif. Pour les investisseurs, le document confirme l'arrêt des futures émissions d’actions dans le cadre des plans employés et incitatifs et apporte une clôture réglementaire finale sur la transition de Regulus d’émetteur public à une entité de Novartis.

Regulus Therapeutics Inc. reichte am 25. Juni 2025 die Post-Effective Amendment Nr. 1 zu 20 zuvor wirksamen Form S-8-Registrierungserklärungen ein. Die Änderung deregistriert alle Stammaktien, die registriert, aber unter den Aktienanreizplänen von 2009, 2012, 2019 und 2021, mehreren Anreizplänen sowie den Mitarbeiteraktienkaufplänen von 2012 und 2022 unverkauft oder nicht ausgegeben geblieben waren. Die betroffenen Einreichungen umfassen Registrierungen aus den Jahren 2012 bis 2025 und beziehen sich auf zwei Rückwärtssplits (1:12 im Jahr 2018 und 1:10 im Jahr 2022).

Diese Maßnahme folgt dem Abschluss der im Fusionsvertrag vom 29. April 2025 zwischen Regulus, Novartis AG und Redwood Merger Sub Inc. festgelegten Fusion. Am 25. Juni 2025 fusionierte Redwood Merger Sub mit Regulus, wodurch Regulus eine hundertprozentige Tochtergesellschaft von Novartis wurde. Da das Unternehmen nun privat ist, wurden alle Wertpapierangebote eingestellt, wodurch die ursprünglichen S-8-Registrierungen überflüssig wurden.

Operativ wird Regulus als Non-Accelerated Filer und als kleineres berichtspflichtiges Unternehmen eingestuft. Es sind keine Finanzberichte, Bewertungsdaten oder Pro-forma-Offenlegungen enthalten; die Einreichung dient rein administrativen Zwecken. Für Investoren bestätigt das Dokument das Ende zukünftiger Aktienausgaben im Rahmen von Mitarbeiter- und Anreizplänen und bietet einen abschließenden regulatorischen Abschluss der Umstellung von Regulus vom öffentlichen Emittenten zu einem Teil von Novartis.

NPORT-P: Filer Information

Filer CIK
Filer CCC
Filer Investment Company Type
Is this a LIVE or TEST Filing? LIVE TEST
Would you like a Return Copy?
Is this an electronic copy of an official filing submitted in paper format?

Submission Contact Information

Name
Phone
E-Mail Address

Notification Information

Notify via Filing Website only?
Series ID
Class (Contract) ID

NPORT-P: Part A: General Information

Item A.1. Information about the Registrant.

a. Name of Registrant
b. Investment Company Act file number for Registrant: (e.g., 811-______)
c. CIK number of Registrant
d. LEI of Registrant

e. Address and telephone number of Registrant.
Street Address 1
Street Address 2
City
State, if applicable
Foreign country, if applicable
Zip / Postal Code
Telephone number

Item A.2. Information about the Series.

a. Name of Series.
b. EDGAR series identifier (if any).
c. LEI of Series.

Item A.3. Reporting period.

a. Date of fiscal year-end.
b. Date as of which information is reported.

Item A.4. Final filing

Does the Fund anticipate that this will be its final filing on Form N PORT? Yes No

NPORT-P: Part B: Information About the Fund

Report the following information for the Fund and its consolidated subsidiaries.

Item B.1. Assets and liabilities. Report amounts in U.S. dollars.

a. Total assets, including assets attributable to miscellaneous securities reported in Part D.
b. Total liabilities.
c. Net assets.

Item B.2. Certain assets and liabilities. Report amounts in U.S. dollars.

a. Assets attributable to miscellaneous securities reported in Part D.
b. Assets invested in a Controlled Foreign Corporation for the purpose of investing in certain types of instruments such as, but not limited to, commodities.

c. Borrowings attributable to amounts payable for notes payable, bonds, and similar debt, as reported pursuant to rule 6-04(13)(a) of Regulation S-X [17 CFR 210.6-04(13)(a)].

Amounts payable within one year.
Banks or other financial institutions for borrowings.
Controlled companies.
Other affiliates.
Others.
Amounts payable after one year.
Banks or other financial institutions for borrowings.
Controlled companies.
Other affiliates.
Others.

d. Payables for investments purchased either (i) on a delayed delivery, when-issued, or other firm commitment basis, or (ii) on a standby commitment basis.

(i) On a delayed delivery, when-issued, or other firm commitment basis:
(ii) On a standby commitment basis:
e. Liquidation preference of outstanding preferred stock issued by the Fund.
f. Cash and cash equivalents not reported in Parts C and D.

Item B.3. Portfolio level risk metrics.

If the average value of the Fund's debt securities positions for the previous three months, in the aggregate, exceeds 25% or more of the Fund's net asset value, provide:

c. Credit Spread Risk (SDV01, CR01 or CS01). Provide the change in value of the portfolio resulting from a 1 basis point change in credit spreads where the shift is applied to the option adjusted spread, aggregated by investment grade and non-investment grade exposures, for each of the following maturities: 3 month, 1 year, 5 years, 10 years, and 30 years.

Investment grade.
Maturity period.
3 month.
1 year.
5 years.
10 years.
30 years.
Non-Investment grade.
Maturity period.
3 month.
1 year.
5 years.
10 years.
30 years.

For purposes of Item B.3., calculate value as the sum of the absolute values of:
(i) the value of each debt security,
(ii) the notional value of each swap, including, but not limited to, total return swaps, interest rate swaps, and credit default swaps, for which the underlying reference asset or assets are debt securities or an interest rate;
(iii) the notional value of each futures contract for which the underlying reference asset or assets are debt securities or an interest rate; and
(iv) the delta-adjusted notional value of any option for which the underlying reference asset is an asset described in clause (i),(ii), or (iii).

Report zero for maturities to which the Fund has no exposure. For exposures that fall between any of the listed maturities in (a) and (b), use linear interpolation to approximate exposure to each maturity listed above. For exposures outside of the range of maturities listed above, include those exposures in the nearest maturity.


Item B.4. Securities lending.

a. For each borrower in any securities lending transaction, provide the following information:

b. Did any securities lending counterparty provide any non-cash collateral? Yes No

Item B.5. Return information.

a. Monthly total returns of the Fund for each of the preceding three months. If the Fund is a Multiple Class Fund, report returns for each class. Such returns shall be calculated in accordance with the methodologies outlined in Item 26(b) (1) of Form N-1A, Instruction 13 to sub-Item 1 of Item 4 of Form N-2, or Item 26(b) (i) of Form N-3, as applicable.

Monthly Total Return Record: 1
Monthly total returns of the Fund for each of the preceding three months - Month 1.
Monthly total returns of the Fund for each of the preceding three months - Month 2.
Monthly total returns of the Fund for each of the preceding three months - Month 3.
b. Class identification number(s) (if any) of the Class(es) for which returns are reported.

c. For each of the preceding three months, monthly net realized gain (loss) and net change in unrealized appreciation (or depreciation) attributable to derivatives for each of the following categories: commodity contracts, credit contracts, equity contracts, foreign exchange contracts, interest rate contracts, and other contracts. Within each such asset category, further report the same information for each of the following types of derivatives instrument: forward, future, option, swaption, swap, warrant, and other. Report in U.S. dollars. Losses and depreciation shall be reported as negative numbers.

Asset category.
Monthly net realized gain(loss) - Month 1
Monthly net change in unrealized appreciation (or depreciation) - Month 1
Monthly net realized gain(loss) - Month 2
Monthly net change in unrealized appreciation (or depreciation) - Month 2
Monthly net realized gain(loss) - Month 3
Monthly net change in unrealized appreciation (or depreciation) - Month 3
Instrument type.
Monthly net realized gain(loss) - Month 1
Monthly net change in unrealized appreciation (or depreciation) - Month 1
Monthly net realized gain(loss) - Month 2
Monthly net change in unrealized appreciation (or depreciation) - Month 2
Monthly net realized gain(loss) - Month 3
Monthly net change in unrealized appreciation (or depreciation) - Month 3

d. For each of the preceding three months, monthly net realized gain (loss) and net change in unrealized appreciation (or depreciation) attributable to investment other than derivatives. Report in U.S. dollars. Losses and depreciation shall be reported as negative numbers.
Month 1


Monthly net realized gain(loss) - Month 1
Monthly net change in unrealized appreciation (or depreciation) - Month 1
Month 2
Monthly net realized gain(loss) - Month 2
Monthly net change in unrealized appreciation (or depreciation) - Month 2
Month 3
Monthly net realized gain(loss) - Month 3
Monthly net change in unrealized appreciation (or depreciation) - Month 3

Item B.6. Flow information.

Provide the aggregate dollar amounts for sales and redemptions/repurchases of Fund shares during each of the preceding three months. If shares of the Fund are held in omnibus accounts, for purposes of calculating the Fund's sales, redemptions, and repurchases, use net sales or redemptions/repurchases from such omnibus accounts. The amounts to be reported under this Item should be after any front-end sales load has been deducted and before any deferred or contingent deferred sales load or charge has been deducted. Shares sold shall include shares sold by the Fund to a registered unit investment trust. For mergers and other acquisitions, include in the value of shares sold any transaction in which the Fund acquired the assets of another investment company or of a personal holding company in exchange for its own shares. For liquidations, include in the value of shares redeemed any transaction in which the Fund liquidated all or part of its assets. Exchanges are defined as the redemption or repurchase of shares of one Fund or series and the investment of all or part of the proceeds in shares of another Fund or series in the same family of investment companies.
Month 1
a. Total net asset value of shares sold (including exchanges but excluding reinvestment of dividends and distributions).
b. Total net asset value of shares sold in connection with reinvestments of dividends and distributions.
c. Total net asset value of shares redeemed or repurchased, including exchanges.
Month 2
a. Total net asset value of shares sold (including exchanges but excluding reinvestment of dividends and distributions).
b. Total net asset value of shares sold in connection with reinvestments of dividends and distributions.
c. Total net asset value of shares redeemed or repurchased, including exchanges.
Month 3
a. Total net asset value of shares sold (including exchanges but excluding reinvestment of dividends and distributions).
b. Total net asset value of shares sold in connection with reinvestments of dividends and distributions.
c. Total net asset value of shares redeemed or repurchased, including exchanges.

Item B.7. Highly Liquid Investment Minimum information.

a. If applicable, provide the Fund's current Highly Liquid Investment Minimum.
b. If applicable, provide the number of days that the Fund's holdings in Highly Liquid Investments fell below the Fund's Highly Liquid Investment Minimum during the reporting period.
c. Did the Fund's Highly Liquid Investment Minimum change during the reporting period? Yes No N/A

Item B.8. Derivatives Transactions.

For portfolio investments of open-end management investment companies, provide the percentage of the Fund's Highly Liquid Investments that it has pledged as margin or collateral in connection with derivatives transactions that are classified among the following categories as specified in rule 22e-4 [17 CFR 270.22e-4]:

(1) Moderately Liquid Investments
(2) Less Liquid Investments
(3) Illiquid Investments

For purposes of Item B.8, when computing the required percentage, the denominator should only include assets (and exclude liabilities) that are categorized by the Fund as Highly Liquid Investments.

Classification

Item B.9. Derivatives Exposure for limited derivatives users.

If the Fund is excepted from the rule 18f-4 [17 CFR 270.18f-4] program requirement and limit on fund leverage risk under rule 18f-4(c)(4) [17 CFR 270.18f-4(c)(4)], provide the following information:

a. Derivatives exposure (as defined in rule 18f-4(a) [17 CFR 270.18f-4(a)]), reported as a percentage of the Fund's net asset value.
b. Exposure from currency derivatives that hedge currency risks, as provided in rule 18f-4(c)(4)(i)(B) [17 CFR 270.18f-4(c)(4)(i)(B)], reported as a percentage of the Fund's net asset value.
c. Exposure from interest rate derivatives that hedge interest rate risks, as provided in rule 18f-4(c)(4)(i)(B) [17 CFR 270.18f-4(c)(4)(i)(B)], reported as a percentage of the Fund's net asset value.
d. The number of business days, if any, in excess of the five-business-day period described in rule 18f-4(c)(4)(ii) [17 CFR 270.18f-4(c)(4)(ii)], that the Fund's derivatives exposure exceeded 10 percent of its net assets during the reporting period.

Item B.10. VaR information.

For Funds subject to the limit on fund leverage risk described in rule 18f-4(c)(2) [17 CFR 270.18f-4(c)(2)], provide the following information, as determined in accordance with the requirement under rule 18f-4(c)(2)(ii) to determine the fund's compliance with the applicable VaR test at least once each business day:

a. Median daily VaR during the reporting period, reported as a percentage of the Fund's net asset value.
b. For Funds that were subject to the Relative VaR Test during the reporting period, provide:
i. As applicable, the name of the Fund's Designated Index, or a statement that the Fund's Designated Reference Portfolio is the Fund's Securities Portfolio.
ii. As applicable, the index identifier for the Fund's Designated Index.
iii. Median VaR Ratio during the reporting period, reported as a percentage of the VaRof the Fund's Designated Reference Portfolio.
c. Backtesting Results. Number of exceptions that the Fund identified as a result of its backtesting of its VaR calculation model (as described in rule 18f-4(c)(1)(iv) [17 CFR 270.18f-4(c)(1)(iv)] during the reporting period.

NPORT-P: Part C: Schedule of Portfolio Investments

For each investment held by the Fund and its consolidated subsidiaries, disclose the information requested in Part C. A Fund may report information for securities in an aggregate amount not exceeding five percent of its total assets as miscellaneous securities in Part D in lieu of reporting those securities in Part C, provided that the securities so listed are not restricted, have been held for not more than one year prior to the end of the reporting period covered by this report, and have not been previously reported by name to the shareholders of the Fund or to any exchange, or set forth in any registration statement, application, or report to shareholders or otherwise made available to the public.

Item C.1. Identification of investment.

a. Name of issuer (if any).
b. LEI (if any) of issuer. In the case of a holding in a fund that is a series of a series trust, report the LEI of the series.
c. Title of the issue or description of the investment.
d. CUSIP (if any).

At least one of the following other identifiers:

Identifier.
Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Description of other unique identifier.

Item C.2. Amount of each investment.

Balance. Indicate whether amount is expressed in number of shares, principal amount, or other units. For derivatives contracts, as applicable, provide the number of contracts.

Balance
Units
Description of other units.
Currency. Indicate the currency in which the investment is denominated.
Value. Report values in U.S. dollars. If currency of investment is not denominated in U.S. dollars, provide the exchange rate used to calculate value.
Exchange rate.
Percentage value compared to net assets of the Fund.

Item C.3. Indicate payoff profile among the following categories (long, short, N/A). For derivatives, respond N/A to this Item and respond to the relevant payoff profile question in Item C.11.

Payoff profile. Long Short N/A

Item C.4. Asset and issuer type. Select the category that most closely identifies the instrument among each of the following:

Asset type (short-term investment vehicle (e.g., money market fund, liquidity pool, or other cash management vehicle), repurchase agreement, equity-common, equity-preferred, debt, derivative-commodity, derivative-credit, derivative-equity, derivative-foreign exchange, derivative-interest rate, derivatives-other, structured note, loan, ABS-mortgage backed security, ABS-asset backed commercial paper, ABS-collateralized bond/debt obligation, ABS-other, commodity, real estate, other). If "other," provide a brief description.
Issuer type (corporate, U.S. Treasury, U.S. government agency, U.S. government sponsored entity, municipal, non-U.S. sovereign, private fund, registered fund, other). If "other", provide a brief description.
If "other", provide a brief description.

Item C.5. Country of investment or issuer.

Report the ISO country code that corresponds to the country where the issuer is organized.
If different from the country where the issuer is organized, also report the ISO country code that corresponds to the country of investment or issuer based on the concentrations of the risk and economic exposure of the investments.

Item C.6. Is the investment a Restricted Security?

Is the investment a Restricted Security? Yes No

Item C.7.

a. Liquidity classification information. For portfolio investments of open-end management investment companies, provide the liquidity classification(s) for each portfolio investment among the following categories as specified in rule 22e-4 [17 CFR 270.22e-4]. For portfolio investments with multiple liquidity classifications, indicate the percentage amount attributable to each classification.

i. Highly Liquid Investments
ii. Moderately Liquid Investments
iii. Less Liquid Investments
iv. Illiquid Investments
Category.

b. If attributing multiple classification categories to the holding, indicate which of the three circumstances listed in the Instructions to Item C.7 is applicable.

Instructions to Item C.7 Funds may choose to indicate the percentage amount of a holding attributable to multiple classification categories only in the following circumstances: (1) if portions of the position have differing liquidity features that justify treating the portions separately; (2) if a fund has multiple sub-advisers with differing liquidity views; or (3) if the fund chooses to classify the position through evaluation of how long it would take to liquidate the entire position (rather than basing it on the sizes it would reasonably anticipated trading). In (1) and (2), a fund would classify using the reasonably anticipated trade size for each portion of the position.

Item C.8. Indicate the level within the fair value hierarchy in which the fair value measurements fall pursuant to U.S. Generally Accepted Accounting Principles (ASC 820, Fair Value Measurement). [1/2/3] Report "N/A" if the investment does not have a level associated with it (i.e., net asset value used as the practical expedient).

Indicate the level within the fair value hierarchy in which the fair value measurements fall pursuant to U.S. Generally Accepted Accounting Principles 7(ASC 820, Fair Value Measurement). [1/2/3] Report "N/A" if the investment does not have a level associated with it (i.e., net asset value used as the practical expedient). 1 2 3 N/A

Item C.9. For debt securities

For debt securities, also provide:

a. Maturity date.

b. Coupon.

i. Select the category that most closely reflects the coupon type among the following (fixed, floating, variable, none).
ii. Annualized rate.
c. Currently in default? [Y/N] Yes No
d. Are there any interest payments in arrears or have any coupon payments been legally deferred by the issuer? [Y/N] Yes No
e. Is any portion of the interest paid in kind? [Y/N] Enter "N" if the interest may be paid in kind but is not actually paid in kind or if the Fund has the option of electing in-kind payment and has elected to be paid in-kind. Yes No

f. For convertible securities, also provide:

i. Mandatory convertible? [Y/N] Yes No
ii. Contingent convertible? [Y/N] Yes No

iii. Description of the reference instrument, including the name of issuer, title of issue, and currency in which denominated, as well as CUSIP of reference instrument, ISIN (if CUSIP is not available), ticker (if CUSIP and ISIN are not available), or other identifier (if CUSIP, ISIN, and ticker are not available).
If other identifier provided, indicate the type of identifier used.

v. Delta (if applicable).

Item C.10. For repurchase and reverse repurchase agreements, also provide:

a. Select the category that reflects the transaction (repurchase, reverse repurchase). Select "repurchase agreement" if the Fund is the cash lender and receives collateral. Select "reverse repurchase agreement" if the Fund is the cash borrower and posts collateral. Repurchase Reverse repurchase

b. Counterparty.

i. Cleared by central counterparty? [Y/N] If Y, provide the name of the central counterparty. Yes No

ii. If N, provide the name and LEI (if any) of counterparty.

c. Tri-party? Yes No
d. Repurchase rate.
e. Maturity date.

f. Provide the following information concerning the securities subject to the repurchase agreement (i.e., collateral). If multiple securities of an issuer are subject to the repurchase agreement, those securities may be aggregated in responding to Items C.10.f.i-iii.

Item C.11. For derivatives, also provide:

a. Type of derivative instrument that most closely represents the investment, selected from among the following (forward, future, option, swaption, swap (including but not limited to total return swaps, credit default swaps, and interest rate swaps), warrant, other).

b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Record: 1
Name of counterparty.
LEI (if any) of counterparty.
i. Type, selected from among the following (put, call). Respond call for warrants. Put Call
ii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased

3. If the reference instrument is neither a derivative or an index, the description of the reference instrument shall include the name of issuer and title of issue, as well as CUSIP of the reference instrument, ISIN (if CUSIP is not available), ticker if (CUSIP and ISIN are not available), or other identifier (if CUSIP, ISIN, and ticker are not available).

Name of issuer.
Title of issue.

At least one of the following other identifiers:

Identifier.
CUSIP.
Identifier.
ISIN (if CUSIP is not available).
Identifier.
Ticker (if CUSIP and ISIN are not available).

iv. Number of shares or principal amount of underlying reference instrument per contract.

Number of shares.
v. Exercise price or rate.
vi. Exercise Price Currency Code
vii. Expiration date.
viii. Delta.
ix. Unrealized appreciation or depreciation. Depreciation shall be reported as a negative number.

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No

NPORT-P: Part C: Schedule of Portfolio Investments

For each investment held by the Fund and its consolidated subsidiaries, disclose the information requested in Part C. A Fund may report information for securities in an aggregate amount not exceeding five percent of its total assets as miscellaneous securities in Part D in lieu of reporting those securities in Part C, provided that the securities so listed are not restricted, have been held for not more than one year prior to the end of the reporting period covered by this report, and have not been previously reported by name to the shareholders of the Fund or to any exchange, or set forth in any registration statement, application, or report to shareholders or otherwise made available to the public.

Item C.1. Identification of investment.

a. Name of issuer (if any).
b. LEI (if any) of issuer. In the case of a holding in a fund that is a series of a series trust, report the LEI of the series.
c. Title of the issue or description of the investment.
d. CUSIP (if any).

At least one of the following other identifiers:

Identifier.
Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Description of other unique identifier.

Item C.2. Amount of each investment.

Balance. Indicate whether amount is expressed in number of shares, principal amount, or other units. For derivatives contracts, as applicable, provide the number of contracts.

Balance
Units
Description of other units.
Currency. Indicate the currency in which the investment is denominated.
Value. Report values in U.S. dollars. If currency of investment is not denominated in U.S. dollars, provide the exchange rate used to calculate value.
Exchange rate.
Percentage value compared to net assets of the Fund.

Item C.3. Indicate payoff profile among the following categories (long, short, N/A). For derivatives, respond N/A to this Item and respond to the relevant payoff profile question in Item C.11.

Payoff profile. Long Short N/A

Item C.4. Asset and issuer type. Select the category that most closely identifies the instrument among each of the following:

Asset type (short-term investment vehicle (e.g., money market fund, liquidity pool, or other cash management vehicle), repurchase agreement, equity-common, equity-preferred, debt, derivative-commodity, derivative-credit, derivative-equity, derivative-foreign exchange, derivative-interest rate, derivatives-other, structured note, loan, ABS-mortgage backed security, ABS-asset backed commercial paper, ABS-collateralized bond/debt obligation, ABS-other, commodity, real estate, other). If "other," provide a brief description.
Issuer type (corporate, U.S. Treasury, U.S. government agency, U.S. government sponsored entity, municipal, non-U.S. sovereign, private fund, registered fund, other). If "other", provide a brief description.
If "other", provide a brief description.

Item C.5. Country of investment or issuer.

Report the ISO country code that corresponds to the country where the issuer is organized.
If different from the country where the issuer is organized, also report the ISO country code that corresponds to the country of investment or issuer based on the concentrations of the risk and economic exposure of the investments.

Item C.6. Is the investment a Restricted Security?

Is the investment a Restricted Security? Yes No

Item C.7.

a. Liquidity classification information. For portfolio investments of open-end management investment companies, provide the liquidity classification(s) for each portfolio investment among the following categories as specified in rule 22e-4 [17 CFR 270.22e-4]. For portfolio investments with multiple liquidity classifications, indicate the percentage amount attributable to each classification.

i. Highly Liquid Investments
ii. Moderately Liquid Investments
iii. Less Liquid Investments
iv. Illiquid Investments
Category.

b. If attributing multiple classification categories to the holding, indicate which of the three circumstances listed in the Instructions to Item C.7 is applicable.

Instructions to Item C.7 Funds may choose to indicate the percentage amount of a holding attributable to multiple classification categories only in the following circumstances: (1) if portions of the position have differing liquidity features that justify treating the portions separately; (2) if a fund has multiple sub-advisers with differing liquidity views; or (3) if the fund chooses to classify the position through evaluation of how long it would take to liquidate the entire position (rather than basing it on the sizes it would reasonably anticipated trading). In (1) and (2), a fund would classify using the reasonably anticipated trade size for each portion of the position.

Item C.8. Indicate the level within the fair value hierarchy in which the fair value measurements fall pursuant to U.S. Generally Accepted Accounting Principles (ASC 820, Fair Value Measurement). [1/2/3] Report "N/A" if the investment does not have a level associated with it (i.e., net asset value used as the practical expedient).

Indicate the level within the fair value hierarchy in which the fair value measurements fall pursuant to U.S. Generally Accepted Accounting Principles 7(ASC 820, Fair Value Measurement). [1/2/3] Report "N/A" if the investment does not have a level associated with it (i.e., net asset value used as the practical expedient). 1 2 3 N/A

Item C.9. For debt securities

For debt securities, also provide:

a. Maturity date.

b. Coupon.

i. Select the category that most closely reflects the coupon type among the following (fixed, floating, variable, none).
ii. Annualized rate.
c. Currently in default? [Y/N] Yes No
d. Are there any interest payments in arrears or have any coupon payments been legally deferred by the issuer? [Y/N] Yes No
e. Is any portion of the interest paid in kind? [Y/N] Enter "N" if the interest may be paid in kind but is not actually paid in kind or if the Fund has the option of electing in-kind payment and has elected to be paid in-kind. Yes No

f. For convertible securities, also provide:

i. Mandatory convertible? [Y/N] Yes No
ii. Contingent convertible? [Y/N] Yes No

iii. Description of the reference instrument, including the name of issuer, title of issue, and currency in which denominated, as well as CUSIP of reference instrument, ISIN (if CUSIP is not available), ticker (if CUSIP and ISIN are not available), or other identifier (if CUSIP, ISIN, and ticker are not available).
If other identifier provided, indicate the type of identifier used.

v. Delta (if applicable).

Item C.10. For repurchase and reverse repurchase agreements, also provide:

a. Select the category that reflects the transaction (repurchase, reverse repurchase). Select "repurchase agreement" if the Fund is the cash lender and receives collateral. Select "reverse repurchase agreement" if the Fund is the cash borrower and posts collateral. Repurchase Reverse repurchase

b. Counterparty.

i. Cleared by central counterparty? [Y/N] If Y, provide the name of the central counterparty. Yes No

ii. If N, provide the name and LEI (if any) of counterparty.

c. Tri-party? Yes No
d. Repurchase rate.
e. Maturity date.

f. Provide the following information concerning the securities subject to the repurchase agreement (i.e., collateral). If multiple securities of an issuer are subject to the repurchase agreement, those securities may be aggregated in responding to Items C.10.f.i-iii.

Item C.11. For derivatives, also provide:

a. Type of derivative instrument that most closely represents the investment, selected from among the following (forward, future, option, swaption, swap (including but not limited to total return swaps, credit default swaps, and interest rate swaps), warrant, other).

b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Record: 1
Name of counterparty.
LEI (if any) of counterparty.
i. Type, selected from among the following (put, call). Respond call for warrants. Put Call
ii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased

3. If the reference instrument is neither a derivative or an index, the description of the reference instrument shall include the name of issuer and title of issue, as well as CUSIP of the reference instrument, ISIN (if CUSIP is not available), ticker if (CUSIP and ISIN are not available), or other identifier (if CUSIP, ISIN, and ticker are not available).

Name of issuer.
Title of issue.

At least one of the following other identifiers:

Identifier.
CUSIP.
Identifier.
ISIN (if CUSIP is not available).
Identifier.
Ticker (if CUSIP and ISIN are not available).

iv. Number of shares or principal amount of underlying reference instrument per contract.

Number of shares.
v. Exercise price or rate.
vi. Exercise Price Currency Code
vii. Expiration date.
viii. Delta.
ix. Unrealized appreciation or depreciation. Depreciation shall be reported as a negative number.

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No

NPORT-P: Part C: Schedule of Portfolio Investments

For each investment held by the Fund and its consolidated subsidiaries, disclose the information requested in Part C. A Fund may report information for securities in an aggregate amount not exceeding five percent of its total assets as miscellaneous securities in Part D in lieu of reporting those securities in Part C, provided that the securities so listed are not restricted, have been held for not more than one year prior to the end of the reporting period covered by this report, and have not been previously reported by name to the shareholders of the Fund or to any exchange, or set forth in any registration statement, application, or report to shareholders or otherwise made available to the public.

Item C.1. Identification of investment.

a. Name of issuer (if any).
b. LEI (if any) of issuer. In the case of a holding in a fund that is a series of a series trust, report the LEI of the series.
c. Title of the issue or description of the investment.
d. CUSIP (if any).

At least one of the following other identifiers:

Identifier.
Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Description of other unique identifier.

Item C.2. Amount of each investment.

Balance. Indicate whether amount is expressed in number of shares, principal amount, or other units. For derivatives contracts, as applicable, provide the number of contracts.

Balance
Units
Description of other units.
Currency. Indicate the currency in which the investment is denominated.
Value. Report values in U.S. dollars. If currency of investment is not denominated in U.S. dollars, provide the exchange rate used to calculate value.
Exchange rate.
Percentage value compared to net assets of the Fund.

Item C.3. Indicate payoff profile among the following categories (long, short, N/A). For derivatives, respond N/A to this Item and respond to the relevant payoff profile question in Item C.11.

Payoff profile. Long Short N/A

Item C.4. Asset and issuer type. Select the category that most closely identifies the instrument among each of the following:

Asset type (short-term investment vehicle (e.g., money market fund, liquidity pool, or other cash management vehicle), repurchase agreement, equity-common, equity-preferred, debt, derivative-commodity, derivative-credit, derivative-equity, derivative-foreign exchange, derivative-interest rate, derivatives-other, structured note, loan, ABS-mortgage backed security, ABS-asset backed commercial paper, ABS-collateralized bond/debt obligation, ABS-other, commodity, real estate, other). If "other," provide a brief description.
Issuer type (corporate, U.S. Treasury, U.S. government agency, U.S. government sponsored entity, municipal, non-U.S. sovereign, private fund, registered fund, other). If "other", provide a brief description.
If "other", provide a brief description.

Item C.5. Country of investment or issuer.

Report the ISO country code that corresponds to the country where the issuer is organized.
If different from the country where the issuer is organized, also report the ISO country code that corresponds to the country of investment or issuer based on the concentrations of the risk and economic exposure of the investments.

Item C.6. Is the investment a Restricted Security?

Is the investment a Restricted Security? Yes No

Item C.7.

a. Liquidity classification information. For portfolio investments of open-end management investment companies, provide the liquidity classification(s) for each portfolio investment among the following categories as specified in rule 22e-4 [17 CFR 270.22e-4]. For portfolio investments with multiple liquidity classifications, indicate the percentage amount attributable to each classification.

i. Highly Liquid Investments
ii. Moderately Liquid Investments
iii. Less Liquid Investments
iv. Illiquid Investments
Category.

b. If attributing multiple classification categories to the holding, indicate which of the three circumstances listed in the Instructions to Item C.7 is applicable.

Instructions to Item C.7 Funds may choose to indicate the percentage amount of a holding attributable to multiple classification categories only in the following circumstances: (1) if portions of the position have differing liquidity features that justify treating the portions separately; (2) if a fund has multiple sub-advisers with differing liquidity views; or (3) if the fund chooses to classify the position through evaluation of how long it would take to liquidate the entire position (rather than basing it on the sizes it would reasonably anticipated trading). In (1) and (2), a fund would classify using the reasonably anticipated trade size for each portion of the position.

Item C.8. Indicate the level within the fair value hierarchy in which the fair value measurements fall pursuant to U.S. Generally Accepted Accounting Principles (ASC 820, Fair Value Measurement). [1/2/3] Report "N/A" if the investment does not have a level associated with it (i.e., net asset value used as the practical expedient).

Indicate the level within the fair value hierarchy in which the fair value measurements fall pursuant to U.S. Generally Accepted Accounting Principles 7(ASC 820, Fair Value Measurement). [1/2/3] Report "N/A" if the investment does not have a level associated with it (i.e., net asset value used as the practical expedient). 1 2 3 N/A

Item C.9. For debt securities

For debt securities, also provide:

a. Maturity date.

b. Coupon.

i. Select the category that most closely reflects the coupon type among the following (fixed, floating, variable, none).
ii. Annualized rate.
c. Currently in default? [Y/N] Yes No
d. Are there any interest payments in arrears or have any coupon payments been legally deferred by the issuer? [Y/N] Yes No
e. Is any portion of the interest paid in kind? [Y/N] Enter "N" if the interest may be paid in kind but is not actually paid in kind or if the Fund has the option of electing in-kind payment and has elected to be paid in-kind. Yes No

f. For convertible securities, also provide:

i. Mandatory convertible? [Y/N] Yes No
ii. Contingent convertible? [Y/N] Yes No

iii. Description of the reference instrument, including the name of issuer, title of issue, and currency in which denominated, as well as CUSIP of reference instrument, ISIN (if CUSIP is not available), ticker (if CUSIP and ISIN are not available), or other identifier (if CUSIP, ISIN, and ticker are not available).
If other identifier provided, indicate the type of identifier used.

v. Delta (if applicable).

Item C.10. For repurchase and reverse repurchase agreements, also provide:

a. Select the category that reflects the transaction (repurchase, reverse repurchase). Select "repurchase agreement" if the Fund is the cash lender and receives collateral. Select "reverse repurchase agreement" if the Fund is the cash borrower and posts collateral. Repurchase Reverse repurchase

b. Counterparty.

i. Cleared by central counterparty? [Y/N] If Y, provide the name of the central counterparty. Yes No

ii. If N, provide the name and LEI (if any) of counterparty.

c. Tri-party? Yes No
d. Repurchase rate.
e. Maturity date.

f. Provide the following information concerning the securities subject to the repurchase agreement (i.e., collateral). If multiple securities of an issuer are subject to the repurchase agreement, those securities may be aggregated in responding to Items C.10.f.i-iii.

Item C.11. For derivatives, also provide:

a. Type of derivative instrument that most closely represents the investment, selected from among the following (forward, future, option, swaption, swap (including but not limited to total return swaps, credit default swaps, and interest rate swaps), warrant, other).

b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Record: 1
Name of counterparty.
LEI (if any) of counterparty.
i. Type, selected from among the following (put, call). Respond call for warrants. Put Call
ii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased

3. If the reference instrument is neither a derivative or an index, the description of the reference instrument shall include the name of issuer and title of issue, as well as CUSIP of the reference instrument, ISIN (if CUSIP is not available), ticker if (CUSIP and ISIN are not available), or other identifier (if CUSIP, ISIN, and ticker are not available).

Name of issuer.
Title of issue.

At least one of the following other identifiers:

Identifier.
CUSIP.
Identifier.
ISIN (if CUSIP is not available).
Identifier.
Ticker (if CUSIP and ISIN are not available).

iv. Number of shares or principal amount of underlying reference instrument per contract.

Number of shares.
v. Exercise price or rate.
vi. Exercise Price Currency Code
vii. Expiration date.
viii. Delta.
ix. Unrealized appreciation or depreciation. Depreciation shall be reported as a negative number.

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No

NPORT-P: Part C: Schedule of Portfolio Investments

For each investment held by the Fund and its consolidated subsidiaries, disclose the information requested in Part C. A Fund may report information for securities in an aggregate amount not exceeding five percent of its total assets as miscellaneous securities in Part D in lieu of reporting those securities in Part C, provided that the securities so listed are not restricted, have been held for not more than one year prior to the end of the reporting period covered by this report, and have not been previously reported by name to the shareholders of the Fund or to any exchange, or set forth in any registration statement, application, or report to shareholders or otherwise made available to the public.

Item C.1. Identification of investment.

a. Name of issuer (if any).
b. LEI (if any) of issuer. In the case of a holding in a fund that is a series of a series trust, report the LEI of the series.
c. Title of the issue or description of the investment.
d. CUSIP (if any).

At least one of the following other identifiers:

Identifier.
Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Description of other unique identifier.

Item C.2. Amount of each investment.

Balance. Indicate whether amount is expressed in number of shares, principal amount, or other units. For derivatives contracts, as applicable, provide the number of contracts.

Balance
Units
Description of other units.
Currency. Indicate the currency in which the investment is denominated.
Value. Report values in U.S. dollars. If currency of investment is not denominated in U.S. dollars, provide the exchange rate used to calculate value.
Exchange rate.
Percentage value compared to net assets of the Fund.

Item C.3. Indicate payoff profile among the following categories (long, short, N/A). For derivatives, respond N/A to this Item and respond to the relevant payoff profile question in Item C.11.

Payoff profile. Long Short N/A

Item C.4. Asset and issuer type. Select the category that most closely identifies the instrument among each of the following:

Asset type (short-term investment vehicle (e.g., money market fund, liquidity pool, or other cash management vehicle), repurchase agreement, equity-common, equity-preferred, debt, derivative-commodity, derivative-credit, derivative-equity, derivative-foreign exchange, derivative-interest rate, derivatives-other, structured note, loan, ABS-mortgage backed security, ABS-asset backed commercial paper, ABS-collateralized bond/debt obligation, ABS-other, commodity, real estate, other). If "other," provide a brief description.
Issuer type (corporate, U.S. Treasury, U.S. government agency, U.S. government sponsored entity, municipal, non-U.S. sovereign, private fund, registered fund, other). If "other", provide a brief description.

Item C.5. Country of investment or issuer.

Report the ISO country code that corresponds to the country where the issuer is organized.
If different from the country where the issuer is organized, also report the ISO country code that corresponds to the country of investment or issuer based on the concentrations of the risk and economic exposure of the investments.

Item C.6. Is the investment a Restricted Security?

Is the investment a Restricted Security? Yes No

Item C.7.

a. Liquidity classification information. For portfolio investments of open-end management investment companies, provide the liquidity classification(s) for each portfolio investment among the following categories as specified in rule 22e-4 [17 CFR 270.22e-4]. For portfolio investments with multiple liquidity classifications, indicate the percentage amount attributable to each classification.

i. Highly Liquid Investments
ii. Moderately Liquid Investments
iii. Less Liquid Investments
iv. Illiquid Investments
Category.

b. If attributing multiple classification categories to the holding, indicate which of the three circumstances listed in the Instructions to Item C.7 is applicable.

Instructions to Item C.7 Funds may choose to indicate the percentage amount of a holding attributable to multiple classification categories only in the following circumstances: (1) if portions of the position have differing liquidity features that justify treating the portions separately; (2) if a fund has multiple sub-advisers with differing liquidity views; or (3) if the fund chooses to classify the position through evaluation of how long it would take to liquidate the entire position (rather than basing it on the sizes it would reasonably anticipated trading). In (1) and (2), a fund would classify using the reasonably anticipated trade size for each portion of the position.

Item C.8. Indicate the level within the fair value hierarchy in which the fair value measurements fall pursuant to U.S. Generally Accepted Accounting Principles (ASC 820, Fair Value Measurement). [1/2/3] Report "N/A" if the investment does not have a level associated with it (i.e., net asset value used as the practical expedient).

Indicate the level within the fair value hierarchy in which the fair value measurements fall pursuant to U.S. Generally Accepted Accounting Principles 7(ASC 820, Fair Value Measurement). [1/2/3] Report "N/A" if the investment does not have a level associated with it (i.e., net asset value used as the practical expedient). 1 2 3 N/A

Item C.9. For debt securities

For debt securities, also provide:

a. Maturity date.

b. Coupon.

i. Select the category that most closely reflects the coupon type among the following (fixed, floating, variable, none).
ii. Annualized rate.
c. Currently in default? [Y/N] Yes No
d. Are there any interest payments in arrears or have any coupon payments been legally deferred by the issuer? [Y/N] Yes No
e. Is any portion of the interest paid in kind? [Y/N] Enter "N" if the interest may be paid in kind but is not actually paid in kind or if the Fund has the option of electing in-kind payment and has elected to be paid in-kind. Yes No

f. For convertible securities, also provide:

i. Mandatory convertible? [Y/N] Yes No
ii. Contingent convertible? [Y/N] Yes No

iii. Description of the reference instrument, including the name of issuer, title of issue, and currency in which denominated, as well as CUSIP of reference instrument, ISIN (if CUSIP is not available), ticker (if CUSIP and ISIN are not available), or other identifier (if CUSIP, ISIN, and ticker are not available).
If other identifier provided, indicate the type of identifier used.

v. Delta (if applicable).

Item C.10. For repurchase and reverse repurchase agreements, also provide:

a. Select the category that reflects the transaction (repurchase, reverse repurchase). Select "repurchase agreement" if the Fund is the cash lender and receives collateral. Select "reverse repurchase agreement" if the Fund is the cash borrower and posts collateral. Repurchase Reverse repurchase

b. Counterparty.

i. Cleared by central counterparty? [Y/N] If Y, provide the name of the central counterparty. Yes No

ii. If N, provide the name and LEI (if any) of counterparty.

c. Tri-party? Yes No
d. Repurchase rate.
e. Maturity date.

f. Provide the following information concerning the securities subject to the repurchase agreement (i.e., collateral). If multiple securities of an issuer are subject to the repurchase agreement, those securities may be aggregated in responding to Items C.10.f.i-iii.

Item C.11. For derivatives, also provide:

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No

NPORT-P: Part C: Schedule of Portfolio Investments

For each investment held by the Fund and its consolidated subsidiaries, disclose the information requested in Part C. A Fund may report information for securities in an aggregate amount not exceeding five percent of its total assets as miscellaneous securities in Part D in lieu of reporting those securities in Part C, provided that the securities so listed are not restricted, have been held for not more than one year prior to the end of the reporting period covered by this report, and have not been previously reported by name to the shareholders of the Fund or to any exchange, or set forth in any registration statement, application, or report to shareholders or otherwise made available to the public.

Item C.1. Identification of investment.

a. Name of issuer (if any).
b. LEI (if any) of issuer. In the case of a holding in a fund that is a series of a series trust, report the LEI of the series.
c. Title of the issue or description of the investment.
d. CUSIP (if any).

At least one of the following other identifiers:

Identifier.
Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Description of other unique identifier.

Item C.2. Amount of each investment.

Balance. Indicate whether amount is expressed in number of shares, principal amount, or other units. For derivatives contracts, as applicable, provide the number of contracts.

Balance
Units
Description of other units.
Currency. Indicate the currency in which the investment is denominated.
Value. Report values in U.S. dollars. If currency of investment is not denominated in U.S. dollars, provide the exchange rate used to calculate value.
Exchange rate.
Percentage value compared to net assets of the Fund.

Item C.3. Indicate payoff profile among the following categories (long, short, N/A). For derivatives, respond N/A to this Item and respond to the relevant payoff profile question in Item C.11.

Payoff profile. Long Short N/A

Item C.4. Asset and issuer type. Select the category that most closely identifies the instrument among each of the following:

Asset type (short-term investment vehicle (e.g., money market fund, liquidity pool, or other cash management vehicle), repurchase agreement, equity-common, equity-preferred, debt, derivative-commodity, derivative-credit, derivative-equity, derivative-foreign exchange, derivative-interest rate, derivatives-other, structured note, loan, ABS-mortgage backed security, ABS-asset backed commercial paper, ABS-collateralized bond/debt obligation, ABS-other, commodity, real estate, other). If "other," provide a brief description.
Issuer type (corporate, U.S. Treasury, U.S. government agency, U.S. government sponsored entity, municipal, non-U.S. sovereign, private fund, registered fund, other). If "other", provide a brief description.
If "other", provide a brief description.

Item C.5. Country of investment or issuer.

Report the ISO country code that corresponds to the country where the issuer is organized.
If different from the country where the issuer is organized, also report the ISO country code that corresponds to the country of investment or issuer based on the concentrations of the risk and economic exposure of the investments.

Item C.6. Is the investment a Restricted Security?

Is the investment a Restricted Security? Yes No

Item C.7.

a. Liquidity classification information. For portfolio investments of open-end management investment companies, provide the liquidity classification(s) for each portfolio investment among the following categories as specified in rule 22e-4 [17 CFR 270.22e-4]. For portfolio investments with multiple liquidity classifications, indicate the percentage amount attributable to each classification.

i. Highly Liquid Investments
ii. Moderately Liquid Investments
iii. Less Liquid Investments
iv. Illiquid Investments
Category.

b. If attributing multiple classification categories to the holding, indicate which of the three circumstances listed in the Instructions to Item C.7 is applicable.

Instructions to Item C.7 Funds may choose to indicate the percentage amount of a holding attributable to multiple classification categories only in the following circumstances: (1) if portions of the position have differing liquidity features that justify treating the portions separately; (2) if a fund has multiple sub-advisers with differing liquidity views; or (3) if the fund chooses to classify the position through evaluation of how long it would take to liquidate the entire position (rather than basing it on the sizes it would reasonably anticipated trading). In (1) and (2), a fund would classify using the reasonably anticipated trade size for each portion of the position.

Item C.8. Indicate the level within the fair value hierarchy in which the fair value measurements fall pursuant to U.S. Generally Accepted Accounting Principles (ASC 820, Fair Value Measurement). [1/2/3] Report "N/A" if the investment does not have a level associated with it (i.e., net asset value used as the practical expedient).

Indicate the level within the fair value hierarchy in which the fair value measurements fall pursuant to U.S. Generally Accepted Accounting Principles 7(ASC 820, Fair Value Measurement). [1/2/3] Report "N/A" if the investment does not have a level associated with it (i.e., net asset value used as the practical expedient). 1 2 3 N/A

Item C.9. For debt securities

For debt securities, also provide:

a. Maturity date.

b. Coupon.

i. Select the category that most closely reflects the coupon type among the following (fixed, floating, variable, none).
ii. Annualized rate.
c. Currently in default? [Y/N] Yes No
d. Are there any interest payments in arrears or have any coupon payments been legally deferred by the issuer? [Y/N] Yes No
e. Is any portion of the interest paid in kind? [Y/N] Enter "N" if the interest may be paid in kind but is not actually paid in kind or if the Fund has the option of electing in-kind payment and has elected to be paid in-kind. Yes No

f. For convertible securities, also provide:

i. Mandatory convertible? [Y/N] Yes No
ii. Contingent convertible? [Y/N] Yes No

iii. Description of the reference instrument, including the name of issuer, title of issue, and currency in which denominated, as well as CUSIP of reference instrument, ISIN (if CUSIP is not available), ticker (if CUSIP and ISIN are not available), or other identifier (if CUSIP, ISIN, and ticker are not available).
If other identifier provided, indicate the type of identifier used.

v. Delta (if applicable).

Item C.10. For repurchase and reverse repurchase agreements, also provide:

a. Select the category that reflects the transaction (repurchase, reverse repurchase). Select "repurchase agreement" if the Fund is the cash lender and receives collateral. Select "reverse repurchase agreement" if the Fund is the cash borrower and posts collateral. Repurchase Reverse repurchase

b. Counterparty.

i. Cleared by central counterparty? [Y/N] If Y, provide the name of the central counterparty. Yes No

ii. If N, provide the name and LEI (if any) of counterparty.

c. Tri-party? Yes No
d. Repurchase rate.
e. Maturity date.

f. Provide the following information concerning the securities subject to the repurchase agreement (i.e., collateral). If multiple securities of an issuer are subject to the repurchase agreement, those securities may be aggregated in responding to Items C.10.f.i-iii.

Item C.11. For derivatives, also provide:

a. Type of derivative instrument that most closely represents the investment, selected from among the following (forward, future, option, swaption, swap (including but not limited to total return swaps, credit default swaps, and interest rate swaps), warrant, other).

b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Record: 1
Name of counterparty.
LEI (if any) of counterparty.
i. Type, selected from among the following (put, call). Respond call for warrants. Put Call
ii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased

3. If the reference instrument is neither a derivative or an index, the description of the reference instrument shall include the name of issuer and title of issue, as well as CUSIP of the reference instrument, ISIN (if CUSIP is not available), ticker if (CUSIP and ISIN are not available), or other identifier (if CUSIP, ISIN, and ticker are not available).

Name of issuer.
Title of issue.

At least one of the following other identifiers:

Identifier.
CUSIP.
Identifier.
ISIN (if CUSIP is not available).
Identifier.
Ticker (if CUSIP and ISIN are not available).

iv. Number of shares or principal amount of underlying reference instrument per contract.

Number of shares.
v. Exercise price or rate.
vi. Exercise Price Currency Code
vii. Expiration date.
viii. Delta.
ix. Unrealized appreciation or depreciation. Depreciation shall be reported as a negative number.

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No

NPORT-P: Part E: Explanatory Notes (if any)

The Fund may provide any information it believes would be helpful in understanding the information reported in response to any Item of this Form. The Fund may also explain any assumptions that it made in responding to any Item of this Form. To the extent responses relate to a particular Item, provide the Item number(s), as applicable.

NPORT-P: Signatures

The Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Registrant:
By(Signature):
Name:
Title:
Date:

FAQ

Why did Regulus Therapeutics (RGLS) file a Post-Effective Amendment on Form S-8?

To deregister all shares previously registered but unsold under various equity and employee stock plans after the company’s merger with Novartis AG.

How many registration statements are being affected by the amendment?

The filing covers 20 separate Form S-8 registration statements submitted between 2012 and 2025.

What event triggered the deregistration of Regulus Therapeutics’ securities?

The 25 June 2025 merger whereby Redwood Merger Sub Inc. merged into Regulus, making it a wholly-owned Novartis subsidiary.

Does the filing mean Regulus will issue no further common stock?

Yes. The company has terminated all offerings and sales of its common stock; no new shares will be issued under the listed plans.

What reverse stock splits are referenced in the document?

A 1-for-12 reverse split on 3 Oct 2018 and a 1-for-10 reverse split on 28 Jun 2022 are noted for share calculations.

Is any financial or earnings data included in this amendment?

No. The amendment is strictly administrative and contains no financial statements or earnings information.
Innovator Equity

NYSE:SFLR

SFLR Rankings

SFLR Latest News

SFLR Latest SEC Filings

SFLR Stock Data

25.50M